Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis.
- Husain S Barts and the London School of Medicine and Dentistry, Blizard Institute, Queen Mary University of London, London, UK.
- Allotey J Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- Drymoussi Z Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- Wilks M Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- Fernandez-Felix BM CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.
- Whiley A Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- Dodds J Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- Thangaratinam S Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- McCourt C City University of London, University of London, London, UK.
- Prosdocimi EM Centre for Host-Microbiome Interactions, King's College London, London, UK.
- Wade WG Centre for Host-Microbiome Interactions, King's College London, London, UK.
- de Tejada BM Department of Obstetrics and Gynaecology, Faculty of Medicine, University Hospitals of Geneva, Geneva, Switzerland.
- Zamora J Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- Khan K Women's Health Research Unit, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- Millar M Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
- 2019-04-02
Published in:
- BJOG : an international journal of obstetrics and gynaecology. - 2020
Lactobacillus reuteri
Lactobacillus rhamnosus
Bacterial vaginosis
probiotic
Adult
Double-Blind Method
Female
Humans
Lactobacillus reuteri
Lactobacillus rhamnosus
Microbiota
Pregnancy
Pregnancy Complications, Infectious
Pregnancy Trimester, First
Probiotics
Vagina
Vaginosis, Bacterial
Young Adult
English
OBJECTIVE
To determine the effects on the vaginal microbiota of an oral probiotic preparation administered from early pregnancy.
DESIGN
Randomised, double blind, placebo-controlled trial.
SETTING
Four maternity units in the UK.
POPULATION
Women aged 16 years or older recruited at 9-14 weeks' gestation.
METHODS
Participants were randomly allocated to receive oral capsules of probiotic containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each at 2.5 × 109 colony-forming units (CFUs) or placebo once daily from recruitment until the end of pregnancy.
MAIN OUTCOME MEASURE
Rates of bacterial vaginosis (BV, defined as Nugent score ≥7) at 18-20 weeks' gestation compared by logistic regression adjusted for possible confounders.
RESULTS
The primary analysis included 78% (238/304) of participants who initially consented (probiotic group 123, placebo group 115). Of these participants, 95% (227/238) reported an intake of 93% or more of the required number of capsules. The rates of BV did not differ between groups at 18-20 weeks' gestation (15% (19/123) in the probiotic group vs. 9% (10/115) in the placebo group, adjusted odds ratio 1.82, 95% confidence interval 0.64-5.19). There were also no differences between the groups in the proportion of women colonised with the probiotic strains, Escherichia coli, group B streptococci or other vaginal microbiota. There were no differences in the alpha diversity or composition of the bacterial communities between or within the probiotic and placebo groups at 9-14 and 18-20 weeks' gestation.
CONCLUSIONS
Oral probiotics taken from early pregnancy did not modify the vaginal microbiota.
TWEETABLE ABSTRACT
The oral probiotic preparation used in this study does not prevent BV in pregnant women.
To determine the effects on the vaginal microbiota of an oral probiotic preparation administered from early pregnancy.
DESIGN
Randomised, double blind, placebo-controlled trial.
SETTING
Four maternity units in the UK.
POPULATION
Women aged 16 years or older recruited at 9-14 weeks' gestation.
METHODS
Participants were randomly allocated to receive oral capsules of probiotic containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 each at 2.5 × 109 colony-forming units (CFUs) or placebo once daily from recruitment until the end of pregnancy.
MAIN OUTCOME MEASURE
Rates of bacterial vaginosis (BV, defined as Nugent score ≥7) at 18-20 weeks' gestation compared by logistic regression adjusted for possible confounders.
RESULTS
The primary analysis included 78% (238/304) of participants who initially consented (probiotic group 123, placebo group 115). Of these participants, 95% (227/238) reported an intake of 93% or more of the required number of capsules. The rates of BV did not differ between groups at 18-20 weeks' gestation (15% (19/123) in the probiotic group vs. 9% (10/115) in the placebo group, adjusted odds ratio 1.82, 95% confidence interval 0.64-5.19). There were also no differences between the groups in the proportion of women colonised with the probiotic strains, Escherichia coli, group B streptococci or other vaginal microbiota. There were no differences in the alpha diversity or composition of the bacterial communities between or within the probiotic and placebo groups at 9-14 and 18-20 weeks' gestation.
CONCLUSIONS
Oral probiotics taken from early pregnancy did not modify the vaginal microbiota.
TWEETABLE ABSTRACT
The oral probiotic preparation used in this study does not prevent BV in pregnant women.
- Language
-
- English
- Open access status
- hybrid
- Identifiers
-
- DOI 10.1111/1471-0528.15675
- PMID 30932317
- Persistent URL
- https://folia.unifr.ch/global/documents/269235
Statistics
Document views: 64
File downloads:
- Full-text: 0